Be supported to study part-time at your own pace. The course also offers a pathway – otherwise known as advanced standing – into the Master of Cancer Sciences.
Taking a therapeutic drug from bench to bedside involves a complex, collaborative industry effort.
This Melbourne MicroCert is ideal for health professionals, researchers and other professionals seeking a stronger understanding of the drug commercialisation pipeline and how to take a product from discovery to commercial success.
Delivered in partnership with the VCCC Alliance, the course gives you access to leading industry experts who will provide evidence-based insights and indispensable guidance on the drug development process.
Award: Up to 10 scholarships valued @ $750 toward the full $990 AUD (inc GST) fee
Delivery mode: Online
Duration: 6 Weeks
Course date: 30 October 2023 – 10 December 2023
Theresa Connor, Subject Coordinator
Theresa is a cancer researcher and project manager at the Peter MacCallum Cancer Centre. Theresa has over 10 years’ experience in drug discovery focused on pre-clinical commercialisation. She is a project manager in the Centre of Excellence in Cellular Immunotherapy translational laboratory. Theresa and the VCCC Alliance would also like to acknowledge Lucy Pearce, Dr Julian Clark, Professor Andrew Wilks and Michelle MacNamara for their contribution to this Melbourne MicroCert.
At the end of the course, participants will be able to:
Identify the various economic, intellectual property and strategic alliance considerations involved in embarking on commercial partnerships.
Explain the steps involved from identifying a candidate, to commercialisation of a product through a commercial drug venture pitch.
Applicants need to be available for the full program dates below.
Read more on the University of Melbourne website
All six weeks of the program must be attended. *No previous discounts apply. All applicants will need to submit the application form, incorporate their CV into a single PDF and submit by 5.00pm (AEST) Monday 11 September 2023 to Elizabeth Diao ([email protected]).